AI drug discovery– tag –

1. Where Does AI in Drug Discovery Stand in 2025? Between 2024 and 2025, AI in drug discovery has quietly moved from the “proof-of-concept” phase into a stage where AI-designed molecules are showing signals in human trials. At the same t...

1. Recap: A Cross-Modality “AI in Drug Discovery” Map In Parts 1–6, we walked through: Small molecules × AI Antibodies, bispecifics, and ADCs × AI Nucleic acid and RNA therapeutics × AI Cell and gene therapies × AI Each time, we looked a...

1. Why “Cell & Gene Therapy × AI” Is Both Difficult and Important In Part 6, we focus on cell therapies (e.g., CAR-T, TCR-T) and gene therapies (e.g., AAV or lentiviral vectors). Compared with small molecules, antibodies, or RNA ther...

In the beginner edition, we focused on why the “other 98%” of DNA (non-coding regions) is hard to interpret and why genome AI should be framed as hypothesis generation and prioritization, not as an “answer machine.” This Expert Edition g...

When people hear “genome analysis,” they often imagine a simple story: read DNA, find a mutation, and explain a disease. In reality, the deeper we read, the more often we hit a frustrating wall: we can detect many variants, but we can’t ...

1. Why “Nucleic Acid & RNA Therapeutics × AI” Matters mRNA vaccines, siRNA, antisense oligonucleotides (ASOs), saRNA, and CRISPR guide RNAs have rapidly moved from concept to clinical reality. In these modalities, the design space is...

1. Why “Antibodies & Biologics × AI” Is Different from Small Molecules In Part 3, we focused on small-molecule projects. In Part 4, we turn to antibodies and biologics (including antibodies, bispecifics, antibody–drug conjugates, and...

1. Why Small Molecules Became the Primary Testbed for AI When you scan AI-in-drug-discovery papers and case studies, the first thing you notice is how many of them focus on small molecules. This is not just because small-molecule R&D...

1. Data and Models: The Core of AI in Drug Discovery In Part 1, we mapped where AI can plug into the drug discovery and development value chain and what it can – and cannot – do. In Part 2, we zoom in on the foundations: data and models....

1. Why AI in Drug Discovery Is in the Spotlight Now “AI in drug discovery” has become a buzzword in recent years, but it is not a magic technology that appeared overnight. Traditional in silico approaches – QSAR, docking, and statistical...

Introduction: Past Knowledge Is Now the Starting Point of Future Drug Discovery AI-driven drug discovery has become an increasingly central part of modern pharmaceutical R&D. The speed at which novel drug candidates can be identified...

Strategic Review: Rare Disease, GI, Vaccines, and Innovation Takeda has transformed itself into a global biopharma leader through acquisitions such as Nycomed in 2011 (expanding GI/respiratory reach in Europe), Shire in 2018 (rare diseas...

Strategic Review: Diversifying into Oncology and Immunology Through Innovative Partnerships Boehringer Ingelheim (BI), traditionally strong in cardiovascular and respiratory areas, has pivoted towards oncology and immune diseases over th...

Strategic Overview: Dominance in Diabetes and Obesity with Oncology Expansion Eli Lilly has strengthened its global leadership in diabetes and obesity while expanding into oncology, neuroscience, and gene therapy. With the blockbuster su...

Strategic Review: Investing in ADCs, Rare Diseases, and Biomanufacturing Capabilities AstraZeneca has expanded significantly in oncology through antibody and ADC partnerships, including a high-profile collaboration with Japan’s Daiichi S...

Strategic Review: From mRNA Success to Diversification in Rare Diseases, ADCs, and RNA Editing Pfizer strengthened its biopharmaceutical base with the acquisition of Hospira and GSK’s vaccine assets in 2015, followed by a major expansion...